Predictive biomarkers for personalised anti-cancer drug use

discovery to clinical implementation

Nayef A. Alymani, Murray D. Smith, David J. Williams, Russell D. Petty (Lead / Corresponding author)

    Research output: Contribution to journalArticle

    37 Citations (Scopus)

    Abstract

    A priority translational research objective in cancer medicine is the discovery of novel therapeutic targets for solid tumours. Ideally, co-discovery of predictive biomarkers occurs in parallel to facilitate clinical development of agents and ultimately personalise clinical use. However, the identification of clinically useful predictive biomarkers for solid tumours has proven challenging with many initially promising biomarkers failing to translate into clinically useful applications. In particular, the 'failure' of a predictive biomarker has often only become apparent at a relatively late stage in investigation. Recently, the field has recognised the need to develop a robust clinical biomarker development methodology to facilitate the process. This review discusses the recent progress in this area focusing on the key stages in the biomarker development process: discovery, validation, qualification and implementation. Concentrating on predictive biomarkers for selecting systemic therapies for individual patients in the clinic, the advances and progress in each of these stages in biomarker development are outlined and the key remaining challenges are discussed. Specific examples are discussed to illustrate the challenges identified and how they have been addressed. Overall, we find that significant progress has been made towards a formalised biomarker developmental process. This holds considerable promise for facilitating the translation of predictive biomarkers from discovery to clinical implementation. Further enhancements could eventually be found through alignment with regulatory processes.

    Original languageEnglish
    Pages (from-to)869-879
    Number of pages11
    JournalEuropean Journal of Cancer
    Volume46
    Issue number5
    DOIs
    Publication statusPublished - Mar 2010

    Fingerprint

    Drug Discovery
    Biomarkers
    Neoplasms
    Translational Medical Research
    Tumor Biomarkers
    Medicine
    Therapeutics

    Keywords

    • Antineoplastic Agents
    • Clinical Trials as Topic
    • Drug Discovery
    • Drug Screening Assays, Antitumor
    • Humans
    • Individualized Medicine
    • Neoplasms
    • Reproducibility of Results
    • Translational Medical Research
    • Tumor Markers, Biological

    Cite this

    Alymani, Nayef A. ; Smith, Murray D. ; Williams, David J. ; Petty, Russell D. / Predictive biomarkers for personalised anti-cancer drug use : discovery to clinical implementation. In: European Journal of Cancer. 2010 ; Vol. 46, No. 5. pp. 869-879.
    @article{8bad5d28c18644bdbfaaeb891dacfedc,
    title = "Predictive biomarkers for personalised anti-cancer drug use: discovery to clinical implementation",
    abstract = "A priority translational research objective in cancer medicine is the discovery of novel therapeutic targets for solid tumours. Ideally, co-discovery of predictive biomarkers occurs in parallel to facilitate clinical development of agents and ultimately personalise clinical use. However, the identification of clinically useful predictive biomarkers for solid tumours has proven challenging with many initially promising biomarkers failing to translate into clinically useful applications. In particular, the 'failure' of a predictive biomarker has often only become apparent at a relatively late stage in investigation. Recently, the field has recognised the need to develop a robust clinical biomarker development methodology to facilitate the process. This review discusses the recent progress in this area focusing on the key stages in the biomarker development process: discovery, validation, qualification and implementation. Concentrating on predictive biomarkers for selecting systemic therapies for individual patients in the clinic, the advances and progress in each of these stages in biomarker development are outlined and the key remaining challenges are discussed. Specific examples are discussed to illustrate the challenges identified and how they have been addressed. Overall, we find that significant progress has been made towards a formalised biomarker developmental process. This holds considerable promise for facilitating the translation of predictive biomarkers from discovery to clinical implementation. Further enhancements could eventually be found through alignment with regulatory processes.",
    keywords = "Antineoplastic Agents, Clinical Trials as Topic, Drug Discovery, Drug Screening Assays, Antitumor, Humans, Individualized Medicine, Neoplasms, Reproducibility of Results, Translational Medical Research, Tumor Markers, Biological",
    author = "Alymani, {Nayef A.} and Smith, {Murray D.} and Williams, {David J.} and Petty, {Russell D.}",
    note = "Copyright 2010 Elsevier Ltd. All rights reserved.",
    year = "2010",
    month = "3",
    doi = "10.1016/j.ejca.2010.01.001",
    language = "English",
    volume = "46",
    pages = "869--879",
    journal = "European Journal of Cancer",
    issn = "0959-8049",
    publisher = "Elsevier Ltd",
    number = "5",

    }

    Predictive biomarkers for personalised anti-cancer drug use : discovery to clinical implementation. / Alymani, Nayef A.; Smith, Murray D.; Williams, David J.; Petty, Russell D. (Lead / Corresponding author).

    In: European Journal of Cancer, Vol. 46, No. 5, 03.2010, p. 869-879.

    Research output: Contribution to journalArticle

    TY - JOUR

    T1 - Predictive biomarkers for personalised anti-cancer drug use

    T2 - discovery to clinical implementation

    AU - Alymani, Nayef A.

    AU - Smith, Murray D.

    AU - Williams, David J.

    AU - Petty, Russell D.

    N1 - Copyright 2010 Elsevier Ltd. All rights reserved.

    PY - 2010/3

    Y1 - 2010/3

    N2 - A priority translational research objective in cancer medicine is the discovery of novel therapeutic targets for solid tumours. Ideally, co-discovery of predictive biomarkers occurs in parallel to facilitate clinical development of agents and ultimately personalise clinical use. However, the identification of clinically useful predictive biomarkers for solid tumours has proven challenging with many initially promising biomarkers failing to translate into clinically useful applications. In particular, the 'failure' of a predictive biomarker has often only become apparent at a relatively late stage in investigation. Recently, the field has recognised the need to develop a robust clinical biomarker development methodology to facilitate the process. This review discusses the recent progress in this area focusing on the key stages in the biomarker development process: discovery, validation, qualification and implementation. Concentrating on predictive biomarkers for selecting systemic therapies for individual patients in the clinic, the advances and progress in each of these stages in biomarker development are outlined and the key remaining challenges are discussed. Specific examples are discussed to illustrate the challenges identified and how they have been addressed. Overall, we find that significant progress has been made towards a formalised biomarker developmental process. This holds considerable promise for facilitating the translation of predictive biomarkers from discovery to clinical implementation. Further enhancements could eventually be found through alignment with regulatory processes.

    AB - A priority translational research objective in cancer medicine is the discovery of novel therapeutic targets for solid tumours. Ideally, co-discovery of predictive biomarkers occurs in parallel to facilitate clinical development of agents and ultimately personalise clinical use. However, the identification of clinically useful predictive biomarkers for solid tumours has proven challenging with many initially promising biomarkers failing to translate into clinically useful applications. In particular, the 'failure' of a predictive biomarker has often only become apparent at a relatively late stage in investigation. Recently, the field has recognised the need to develop a robust clinical biomarker development methodology to facilitate the process. This review discusses the recent progress in this area focusing on the key stages in the biomarker development process: discovery, validation, qualification and implementation. Concentrating on predictive biomarkers for selecting systemic therapies for individual patients in the clinic, the advances and progress in each of these stages in biomarker development are outlined and the key remaining challenges are discussed. Specific examples are discussed to illustrate the challenges identified and how they have been addressed. Overall, we find that significant progress has been made towards a formalised biomarker developmental process. This holds considerable promise for facilitating the translation of predictive biomarkers from discovery to clinical implementation. Further enhancements could eventually be found through alignment with regulatory processes.

    KW - Antineoplastic Agents

    KW - Clinical Trials as Topic

    KW - Drug Discovery

    KW - Drug Screening Assays, Antitumor

    KW - Humans

    KW - Individualized Medicine

    KW - Neoplasms

    KW - Reproducibility of Results

    KW - Translational Medical Research

    KW - Tumor Markers, Biological

    U2 - 10.1016/j.ejca.2010.01.001

    DO - 10.1016/j.ejca.2010.01.001

    M3 - Article

    VL - 46

    SP - 869

    EP - 879

    JO - European Journal of Cancer

    JF - European Journal of Cancer

    SN - 0959-8049

    IS - 5

    ER -